Luyan Pharma Co Ltd

Luyan Pharma maintains a capital structure with a debt-to-equity ratio of 1.59, indicating a moderate reliance on debt financing. The company's liquidity position is assessed as medium, with a current ratio of 1.18, suggesting it has sufficient short-term assets to cover its short-term liabilities, but with limited buffer. The company's net cash position is negative after subtracting total debt, signaling potential liquidity constraints.

In terms of profitability, Luyan Pharma's return on equity (ROE) is 3.41%, and its return on assets (ROA) is 0.89%. These figures are below the typical thresholds for strong performance in the pharmaceutical industry, indicating that the company is not generating robust returns relative to its equity or asset base. The company's operating margin is 2.70%, and its net margin is 2.06%, both of which are weak compared to industry benchmarks.

The company's revenue is concentrated in a single geographic market, China, with no disclosed international operations. This concentration increases exposure to domestic regulatory, economic, and competitive risks. No segment-specific revenue breakdown is available, but the company operates as a single business unit.

Luyan Pharma's growth trajectory is modest, with no disclosed revenue growth rates or forward-looking guidance. The company's capital expenditures are negative at -165.83 million CNY, indicating asset disposals or a reduction in investment in physical infrastructure. This may suggest a strategic shift or financial constraints.

The company's risk profile includes medium liquidity risk and low dilution risk. The risk assessment highlights that the company's net cash is negative after subtracting total debt, which could constrain its ability to fund operations or invest in growth without external financing. No dilution risk is currently flagged, and no adjustments have been applied to the valuation metrics.

No recent events, such as filings or transcripts, are available in the provided data to inform the company's current strategic direction or operational developments.

Luyan Pharma Co Ltd (002788.SZ) has undergone a significant update to its corporate taxonomy, with its primary activity now formally classified as "Pharmaceuticals & Medical Research" within the broader "Healthcare" economic sector. This classification change, marked as medium severity, establishes a clearer operational identity for the company, distinguishing its core business focus from previous undefined or generic categorizations. In parallel with the sectoral reclassification, the company’s risk profile has been initialized with specific assessments. The dilution risk is now rated as "low," indicating a stable capital structure with minimal immediate threat of share value erosion from new issuances. This assessment provides investors with a baseline understanding of the equity stability, suggesting that existing shareholders are not currently facing significant pressure from dilutive financing activities. Conversely, the liquidity risk has been assessed as "medium," highlighting a moderate level of concern regarding the company's ability to meet short-term obligations or the ease of trading its shares without significant price impact. This rating serves as a cautionary signal for traders and investors, suggesting that while the capital structure is stable, market depth or cash flow dynamics may require closer monitoring compared to peers with lower liquidity risk profiles. These updates collectively refine the investment thesis for Luyan Pharma by providing a more granular view of its operational and financial characteristics. With no current analyst coverage or index membership noted, these internal risk and taxonomy metrics offer some of the few structured data points available for evaluating the company's standing within the healthcare sector, particularly regarding its stability and market accessibility.

Free cash flow improved by 66.6% year-over-year, indicating significantly better cash generation capabilities compared to the prior period.

Return on equity of 3.41% exceeds the pharmaceutical cohort median of 2.92%, demonstrating superior capital efficiency relative to peers.

Cash conversion ratio of 2.78 ranks as best-in-class within the pharmaceutical cohort, highlighting strong operational cash management.

Revenue grew by 7.1% year-over-year, showing top-line expansion despite broader industry challenges and margin pressures.

Capital expenditure intensity is above median at -3.21% of revenue, suggesting lower reinvestment needs compared to industry peers.

Debt-to-equity ratio of 1.59 places the company in the bottom quartile of the pharmaceutical cohort, indicating high leverage risk.

Net margin of 2.06% trails the pharmaceutical cohort median of 3.9%, indicating inferior bottom-line performance relative to peers.

The company faces high credit risk and medium liquidity risk, posing potential threats to financial stability and operations.

Revenue ¥20.47B, +3,1% YoY; Operating income −2,2% YoY.

• ▍Revenue ¥20.47B, +3,1% YoY
• ▍Operating income −2,2% YoY
• ▍Net income −4,9% YoY
• ▍Free cash flow +47,2% YoY
• ▍Net margin 1.7%